New treatments for cancer involve considerable costs for individuals, but the impact on health systems is rarely discussed. Studying the case of adjuvant chemotherapy for HER2-positive breast cancer, we obtained the NNTs to prevent a relapse in three years with five different treatment regimens, and from its costs compared each strategy for its "cost needed to treat", ie, expense for the health system to avoid one relapse in three years. The use of trastuzumab at the initial adjuvant chemotherapy (FinHER) allows you to benefit from an economic point of view, four to nine times more patients than with extended adjuvant monotherapy as used in other protocols.

Especialidades
       

Clasificación en siicsalud
Entrevista> Expertos de Iberoamérica>

Entrevista completa
Exclusivo para suscriptores
assinantes
Imprimir nota

Extensión de la entrevista:
+/- 1 página impresa en papel A4